Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun;29(3):359-365.
doi: 10.1007/s40620-015-0233-x. Epub 2015 Sep 30.

Epidermal growth factor receptor inhibition with erlotinib ameliorates anti-Thy 1.1-induced experimental glomerulonephritis

Jukka M Rintala  1 , Johanna Savikko  2   3 , Sini E Rintala  2 , Niina Palin  2 , Petri K Koskinen  2   4
Affiliations

Epidermal growth factor receptor inhibition with erlotinib ameliorates anti-Thy 1.1-induced experimental glomerulonephritis

Jukka M Rintala et al. J Nephrol. 2016 Jun.

Abstract

Background: Mesangial proliferative glomerulonephritis is a common glomerular disorder that may lead to end-stage renal disease. Epidermal growth factor (EGF) plays an important role in the regulation of cell growth, proliferation, and differentiation and in the pathology of various renal diseases. Erlotinib is a novel, oral, highly selective tyrosine kinase inhibitor of the EGF receptor. It is clinically used to treat non-small cell lung and pancreatic cancers. Here, we investigated the effect of erlotinib on the progression of mesangioproliferative glomerulonephritis in an experimental model.

Methods: Mesangial glomerulonephritis was induced with anti-rat Thy-1.1 antibody in male Wistar rats weighing 150-160 g. Rats were treated with erlotinib (10 mg/kg/day p.o.) or vehicle only (polyethylene glycol). Native Wistar rat kidneys were used as histological controls. Serum creatinine levels were measured at day 7. Kidneys were harvested 7 days after antibody administration for histology.

Results: Native controls showed no histological signs of glomerular pathology. In the vehicle group, intense glomerular inflammation developed after 7 days and prominent mesangial cell proliferation and glomerular matrix accumulation was seen. Erlotinib was well tolerated and there were no adverse effects during the follow-up period. Erlotinib significantly prevented progression of the glomerular inflammatory response and glomerular mesangial cell proliferation as well as matrix accumulation when compared with the vehicle group. Erlotinib also preserved renal function.

Conclusion: These results indicate that erlotinib prevents the early events of experimental mesangial proliferative glomerulonephritis. Therefore, inhibition of the EGF receptor with erlotinib could prevent the progression of glomerulonephritis also in clinical nephrology.

Keywords: Epidermal growth factor; Erlotinib; Experimental glomerulonephritis.

PubMed Disclaimer

References

    1. Clin Investig. 1993 Oct;71(10):808-11 - PubMed
    1. J Clin Invest. 1988 Sep;82(3):1028-39 - PubMed
    1. Nat Rev Mol Cell Biol. 2003 Aug;4(8):651-7 - PubMed
    1. Transpl Immunol. 2015 Jun;32(3):175-8 - PubMed
    1. Nephrol Dial Transplant. 2005 Nov;20(11):2358-67 - PubMed

LinkOut - more resources